Efficacy of CD34+ Stem Cell Dose in Patients Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation after Total Body Irradiation  Anurag K.

Slides:



Advertisements
Similar presentations
Acute Kidney Injury and the Risk of Mortality in Children Undergoing Hematopoietic Stem Cell Transplantation  Sarah J. Kizilbash, Clifford E. Kashtan,
Advertisements

How to Treat MDS without Stem Cell Transplantation
The Effect of Statin Use at the Time of Autologous Transplant on Response and Survival in Multiple Myeloma  Mehdi Hamadani, Erinn Hade, Don M. Benson,
Increased Levels of Tumor Necrosis Factor α Are Associated with an Increased Risk of Cytomegalovirus Infection after Allogeneic Hematopoietic Stem Cell.
The Outcome of Sibling and Unrelated Donor Allogeneic Stem Cell Transplantation in Adult Patients with Acute Myeloid Leukemia in First Remission Who Were.
Vaccination of Children following Allogeneic Stem Cell Transplantation
Increased Risk of Cervical Dysplasia in Long-Term Survivors of Allogeneic Stem Cell Transplantation—Implications for Screening and HPV Vaccination  Bipin.
Peter Hurley, Suma Konety, Qing Cao, Daniel Weisdorf, Anne Blaes 
Higher Early Monocyte and Total Lymphocyte Counts Are Associated with Better Overall Survival after Standard Total Body Irradiation, Cyclophosphamide,
Allogeneic Stem Cell Transplantation in Myelofibrosis
First- and Second-Line Systemic Treatment of Acute Graft-versus-Host Disease: Recommendations of the American Society of Blood and Marrow Transplantation 
Basal CD34+ Cell Count Predicts Peripheral Blood Stem Cell Mobilization in Healthy Donors after Administration of Granulocyte Colony–Stimulating Factor:
Sabina Kersting, Leo F. Verdonck 
Amyloidosis: 2008 BMT Tandem Meetings (February 13-17, San Diego)
Vascular Endothelial Growth Factor and Activin-A Serum Levels Following Allogeneic Hematopoietic Stem Cell Transplantation  David Nachbaur, Petra Schumacher,
Absolute Lymphocyte Count on Day 30 Is a Surrogate for Robust Hematopoietic Recovery and Strongly Predicts Outcome after T Cell-Depleted Allogeneic Stem.
The Effect of Bone Marrow Plasma Cell Burden on Survival in Patients with Light Chain Amyloidosis Undergoing High-Dose Melphalan and Autologous Stem Cell.
Carbon Monoxide Diffusion Capacity: How Low Can You Go for Hematopoietic Cell Transplantation Eligibility?  Jason W. Chien, Keith M. Sullivan  Biology.
High-Dose Weekly AmBisome Antifungal Prophylaxis in Pediatric Patients Undergoing Hematopoietic Stem Cell Transplantation: A Pharmacokinetic Study  Parinda.
Randomized Double-Blind Study of the Safety and Immunogenicity of Standard-Dose Trivalent Inactivated Influenza Vaccine versus High-Dose Trivalent Inactivated.
Increased Risk of Bone Loss without Fracture Risk in Long-Term Survivors after Allogeneic Stem Cell Transplantation  Bipin N. Savani, Theresa Donohue,
Cytomegalovirus Infection after Allogeneic Transplantation: Comparison of Cord Blood with Peripheral Blood and Marrow Graft Sources  Christopher M. Walker,
Christopher C. Dvorak, Rajni Agarwal, Gary V. Dahl, John J
New Light Chain Amyloid Response Criteria Help Risk Stratification of Patients by Day 100 after Autologous Hematopoietic Cell Transplantation  Anita D'Souza,
A Process to Facilitate Decision Making in Pediatric Stem Cell Transplantation: The Individualized Care Planning and Coordination Model  Justin N. Baker,
Evaluating the Impact of Antithymocyte Globulin on Lung Function at 1 Year after Allogeneic Stem Cell Transplantation  Filippo Milano, Margaret A. Au,
Favorable Outcomes in Patients Surviving 5 or More Years after Allogeneic Hematopoietic Stem Cell Transplantation for Hematologic Malignancies  Robert.
B Cells and Transplantation: An Educational Resource
Higher CD34+ and CD3+ Cell Doses in the Graft Promote Long-Term Survival, and Have No Impact on the Incidence of Severe Acute or Chronic Graft-versus-Host.
Paul A. Hoffmeister, Sangeeta R. Hingorani, Barry E. Storer, K
Relationship of CMV Reactivation and Rabbit Antithymocyte Globulin Administration in Allogeneic Stem Cell Transplant Patients  LeAnne Kennedy, Marie Cavalier,
Allogeneic Hematopoietic Stem Cell Transplantation in Adult Acute Lymphocytic Leukemia: Impact of Donor Source on Survival  Priya Kumar, Todd E. Defor,
Transplantation Conditioning Regimens and Outcomes after Allogeneic Hematopoietic Cell Transplantation in Children and Adolescents with Acute Lymphoblastic.
Favorable Overall Survival with Fully Myeloablative Allogeneic Stem Cell Transplantation for Follicular Lymphoma  John Kuruvilla, Gregory Pond, Richard.
Kamal Kant Singh Abbi, Junting Zheng, Sean M
Pharmacokinetic Evaluation of the Drug Interaction between Intravenous Itraconazole and Intravenous Tacrolimus or Intravenous Cyclosporin A in Allogeneic.
Sabina Kersting, Ronald J. Hené, Hein A. Koomans, Leo F. Verdonck 
Shigeo Fuji, Hermann Einsele, Bipin N. Savani, Markus Kapp 
Central Nervous System Involvement in Acute Myeloid Leukemia Patients Undergoing Hematopoietic Cell Transplantation  Merav Bar, Weigang Tong, Megan Othus,
Allogeneic Stem Cell Transplantation for Aplastic Anemia
Acute Kidney Injury and the Risk of Mortality in Children Undergoing Hematopoietic Stem Cell Transplantation  Sarah J. Kizilbash, Clifford E. Kashtan,
Adverse Prognostic Factors for Morbidity and Mortality During Peripheral Blood Stem Cell Mobilization in Patients with Light Chain Amyloidosis  Jason.
The Contribution of Malglycemia to Mortality among Allogeneic Hematopoietic Cell Transplant Recipients  Marilyn J. Hammer, Corey Casper, Ted A. Gooley,
Outcomes of Cord Blood Transplantation as Salvage Therapy after Graft Failure or Relapse after Prior Allogeneic Transplantation  Rachel B. Salit, Filippo.
CD3+/Tregs Ratio in Donor Grafts Is Linked to Acute Graft-versus-Host Disease and Immunologic Recovery after Allogeneic Peripheral Blood Stem Cell Transplantation 
Steven M. Trifilio, Judy Pi, Jayesh Mehta 
Regression Models for Hazard Rates Versus Cumulative Incidence Probabilities in Hematopoietic Cell Transplantation Data  Brent R. Logan, Mei-Jie Zhang,
What is quality in a transplant program?
Chronic GVHD and Pretransplantation Abnormalities in Pulmonary Function Are the Main Determinants Predicting Worsening Pulmonary Function in Long-term.
Issues of Aging and Geriatric Medicine: Relevance to Cancer Treatment and Hematopoietic Reconstitution  William B. Ershler, Andrew S. Artz, Evan T. Keller 
Rituximab Administration within 6 Months of T Cell-Depleted Allogeneic SCT is Associated with Prolonged Life-Threatening Cytopenias  Zachariah McIver,
Improved Outcome for Peripheral Blood Stem Cell Transplantation for Advanced Primary Myelodysplastic Syndrome  Scott R. Solomon, Bipin N. Savani, Richard.
Systemic Toxoplasmosis Post Allogeneic Stem Cell Transplantation (Allo-SCT): Lessons Learned from HIV?  Marie von Lilienfeld-Toal, MD, Maria Gilleece,
Blood and Marrow Transplant Handbook
Influence of Body Weight on Melphalan Dosing in Autologous Stem Cell Transplantation  Kendall Shultes, Christopher Arp, Keith Stockerl-Goldstein, Kathryn.
Higher Total Nucleated Cell Dose, but Not CD3+, 4+, 8+, or 34+ Cell Dose, Is Associated with Better Overall and Progression-Free Survival after Allogeneic.
Mammen Chandy  Biology of Blood and Marrow Transplantation 
Adult Dual Umbilical Cord Blood Transplantation Using Myeloablative Total Body Irradiation (1350 cGy) and Fludarabine Conditioning  Junya Kanda, David.
Reduced Intensity Conditioning for Allogeneic Hematopoietic Cell Transplantation: Current Perspectives  Brenda M. Sandmaier, Stephen Mackinnon, Richard.
Prediction and prevention of transplant-related mortality from pulmonary causes after total body irradiation and allogeneic stem cell transplantation 
Addition of Plerixafor to Mobilization Regimens in Autologous Peripheral Blood Stem Cell Transplants Does Not Affect the Correlation of Preharvest Hematopoietic.
Treatment versus Transplant for Challenging Hematologic Disorders
Megadose CD34+ Cell Grafts Improve Recovery of T Cell Engraftment but not B Cell Immunity in Patients with Severe Combined Immunodeficiency Disease Undergoing.
A Phase I Study in Adults of Clofarabine Combined with High-Dose Melphalan as Reduced-Intensity Conditioning for Allogeneic Transplantation  Mark H. Kirschbaum,
Outcomes among Patients with Recurrent High-Risk Hematologic Malignancies after Allogeneic Hematopoietic Cell Transplantation  Marco Mielcarek, Barry.
Mary Eapen  Biology of Blood and Marrow Transplantation 
Futility of Relapsed Diffuse Large B Cell Lymphoma Transplantation?
In Memoriam: E. Donnall Thomas
Optimal Donor Selection: Beyond HLA
Prediction of Area under the Cyclosporine Concentration Versus Time Curve in Children Undergoing Hematopoietic Stem Cell Transplantation  L. Lee Dupuis,
Presentation transcript:

Efficacy of CD34+ Stem Cell Dose in Patients Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation after Total Body Irradiation  Anurag K. Singh, Bipin N. Savani, Paul S. Albert, A. John Barrett  Biology of Blood and Marrow Transplantation  Volume 13, Issue 3, Pages 339-344 (March 2007) DOI: 10.1016/j.bbmt.2006.10.029 Copyright © 2007 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 1 (A) A plot of the log HR (relative to the lowest value of CD34+ for no lung dose–reduced TBI) as a function of log-transformed CD34+ dose for all patients. On the original scale (exponentiated log values), the dashed lines correspond to CD34+ dose values of 5.1 and 12.9 × 106 cells/kg. Median survival over this range was at least double the survival associated with the lowest CD 34+ dose. The X value corresponds to the median CD34+ dose on the log scale. Dotted lines are pointwise 95% confidence intervals. (B) This plot shows the relationship between CD34+ dose and mortality with adjustments for lung dose–reduced TBI, CVDC deficit, and age at transplantation. Biology of Blood and Marrow Transplantation 2007 13, 339-344DOI: (10.1016/j.bbmt.2006.10.029) Copyright © 2007 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 2 A plot of the log HR (relative to the lowest value of CD34+ for no lung dose–reduced TBI) as a function of log-transformed CD34+ dose for patients with and without lung dose–reduced TBI. On the original scale, the dashed lines correspond to values of 5.8 and 13.6 × 106 cells/kg without lung dose reduction and 4.3 and 10.2 × 106 cells/kg with lung dose reduction. These regions of lower mortality correspond to a doubling of median survival relative to the lowest CD34+ value within the no lung dose–reduction group and a 5-fold increase in median survival relative to the lowest CD34+ value in the lung dose–reduction group. The dotted lines are pointwise 95% confidence intervals. Biology of Blood and Marrow Transplantation 2007 13, 339-344DOI: (10.1016/j.bbmt.2006.10.029) Copyright © 2007 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 3 This is the same as Figure 1A. The first 2 vertical dashed lines (from right to left) show doses corresponding to 4 and 8 × 106 cells/kg as found by Mohty et al. [12] The second and third vertical dashed lines show the boundaries of 8 and 10 × 106 cells/kg as found by Kamel et al. [10] Biology of Blood and Marrow Transplantation 2007 13, 339-344DOI: (10.1016/j.bbmt.2006.10.029) Copyright © 2007 American Society for Blood and Marrow Transplantation Terms and Conditions